471.75

1.08% -5.16

Madrigal Pharmaceuticals Inc (MDGL)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Madrigal Pharmaceuticals Inc stock is traded at $471.75, with a volume of 312.98K. It is down -1.08% in the last 24 hours and down -13.70% over the past month. Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Previous Close:

$476.91

Open:

$477.48

24h Volume:

312.98K

Relative Volume:

1.11

Market Cap:

$10.90B

Revenue:

$1.13B

Net Income/Loss:

$-309.44M

P/E Ratio:

-36.86

EPS:

-12.8001

Net Cash Flow:

$-275.41M

1W Performance:

-5.54%

1M Performance:

-13.70%

6M Performance:

-10.02%

1Y Performance:

+10.14%

1-Day Range:

$470.53

$483.63

1-Week Range:

$466.06

$505.00

52-Week Range:

$393.61

$615.00

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Name

Madrigal Pharmaceuticals Inc

Sector

Healthcare (1050)

Industry

Biotechnology (591)

Phone

404-380-9263

Address

200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA

Employee

915

Twitter

@MadrigalPharma

Next Earnings Date

2026-11-03

Latest SEC Filings

MDGL's Discussions on Twitter

Compare MDGL vs VRTX, MRNA, REGN, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MDGL Madrigal Pharmaceuticals Inc	471.75	10.90B	1.13B	-309.44M	-275.41M	-12.80
VRTX Vertex Pharmaceuticals Inc	510.08	129.29B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	225.00	89.83B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	746.54	76.86B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	825.03	51.88B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.76	40.67B	742.00K	-1.37B	-1.07B	-7.0731

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-24-26	Resumed	Goldman	Buy
Sep-23-26	Initiated	Citigroup	Buy
Aug-04-26	Upgrade	Wolfe Research	Peer Perform → Outperform
Jul-27-26	Initiated	Wells Fargo	Overweight
Jan-28-26	Initiated	Barclays	Overweight
Jan-06-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-05-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-03-25	Upgrade	BofA Securities	Underperform → Neutral
Oct-15-25	Initiated	Truist	Buy
Sep-04-25	Resumed	H.C. Wainwright	Buy
Feb-28-25	Upgrade	B. Riley Securities	Neutral → Buy
Feb-27-25	Reiterated	H.C. Wainwright	Buy
Jun-28-24	Initiated	Cantor Fitzgerald	Neutral
Jun-11-24	Initiated	Wolfe Research	Outperform
Apr-22-24	Initiated	BofA Securities	Underperform
Mar-15-24	Upgrade	B. Riley Securities	Sell → Neutral
Mar-06-24	Initiated	Citigroup	Buy
Feb-26-24	Downgrade	B. Riley Securities	Neutral → Sell
Dec-20-22	Reiterated	Oppenheimer	Outperform
Dec-19-22	Reiterated	H.C. Wainwright	Buy
Dec-19-22	Reiterated	Piper Sandler	Overweight
Dec-19-22	Upgrade	Raymond James	Underperform → Mkt Perform
Jul-08-22	Downgrade	B. Riley Securities	Buy → Neutral
Oct-07-21	Initiated	Jefferies	Buy
Aug-06-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
May-20-21	Resumed	Goldman	Buy
Nov-24-20	Resumed	Evercore ISI	Outperform
Nov-06-20	Reiterated	H.C. Wainwright	Buy
Jul-31-20	Initiated	Piper Sandler	Overweight
Jun-05-20	Initiated	BMO Capital Markets	Market Perform
May-05-20	Initiated	Chardan Capital Markets	Buy
Jan-30-20	Initiated	Canaccord Genuity	Buy
Jan-09-20	Upgrade	UBS	Neutral → Buy
Nov-07-19	Reiterated	H.C. Wainwright	Buy
Jun-25-19	Initiated	Stifel	Hold
Jun-10-19	Upgrade	B. Riley FBR	Neutral → Buy
Feb-28-19	Reiterated	H.C. Wainwright	Buy
Feb-22-19	Initiated	SVB Leerink	Outperform
Jan-23-19	Initiated	UBS	Neutral
Dec-14-18	Initiated	Wolfe Research	Outperform
Dec-12-18	Initiated	B. Riley FBR	Neutral
Nov-19-18	Downgrade	Raymond James	Mkt Perform → Underperform
Nov-16-18	Upgrade	Evercore ISI	In-line → Outperform
Sep-04-18	Initiated	Citigroup	Buy
Aug-06-18	Downgrade	Goldman	Buy → Neutral
Jun-28-18	Initiated	Raymond James	Mkt Perform

View All

Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News

Oct 07, 2026

Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care? - Zacks Investment Research

Oct 07, 2026

Madrigal Pharmaceuticals stock gets fresh Rezdiffra data - AD HOC NEWS

Oct 07, 2026

Oct 06, 2026

A liver drug improved disease measures across several genetic risk groups - Stock Titan

Oct 06, 2026

Sep 28, 2026

Under an automatic trading plan, director Paul Friedman proposes to sell shares in Madrigal Pharmaceuticals (MDGL). - Stock Titan

Sep 28, 2026

Sep 21, 2026

Madrigal Grants Equity Awards to 27 New Employees - MyChesCo

Sep 21, 2026

Sep 16, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 16, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Sep 16, 2026

Sep 11, 2026

Understanding Momentum Shifts in (MDGL) - Stock Traders Daily

Sep 11, 2026

Madrigal Pharmaceuticals (NASDAQ: MDGL) insider plans another stock sale after recent multimillion-dollar trades - stocktitan.net

Sep 11, 2026

Madrigal Pharma CEO William John Sibold disposes of common shares worth $4.16 million - Bitget

Sep 11, 2026

Sep 10, 2026

Madrigal Pharmaceuticals, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq

Sep 10, 2026

Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com Nigeria

Sep 10, 2026

Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com Canada

Sep 10, 2026

Madrigal at cantor healthcare conference: growth, access and pipeline - investing.com

Sep 10, 2026

Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com UK

Sep 10, 2026

Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? - Yahoo Finance

Sep 10, 2026

Madrigal Pharmaceuticals, Inc. Rings the Closing Bell - Nasdaq

Sep 10, 2026

Sep 09, 2026

Madrigal Pharmaceuticals (NASDAQ: MDGL) exec plans $3.4M stock sale for tax withholding - stocktitan.net

Sep 09, 2026

Sep 07, 2026

September 2026 Nasdaq Stock Market Bell Ceremonies - Nasdaq

Sep 07, 2026

Madrigal Pharmaceuticals (MDGL) Stock Analysis: A 25% Upside Potential In Biotech Innovation - DirectorsTalk Interviews

Sep 07, 2026

Sep 06, 2026

Madrigal to Put MASH Drug Strategy Before Investors at Cantor - MyChesCo

Sep 06, 2026

Sep 02, 2026

Madrigal Pharmaceuticals (MDGL) Leads Healthcare CapEx Growth Am - GuruFocus

Sep 02, 2026

Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - manilatimes.net

Sep 02, 2026

Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewswire

Sep 02, 2026

Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - Yahoo Finance

Sep 02, 2026

Aug 31, 2026